Scientific Frontline: Extended "At a Glance" Summary: Selective ROCK2 Inhibition in Schizophrenia
The Core Concept: Selective inhibition of Rho kinase 2 (ROCK2) via the drug KD025 is a novel therapeutic approach aimed at improving cognitive impairments and behavioral abnormalities in schizophrenia.
Key Distinction/Mechanism: Unlike current antipsychotic medications that primarily target positive symptoms but often cause severe metabolic and motor adverse effects, KD025 selectively inhibits ROCK2 to restore dendritic spine density in the prefrontal cortex without inducing hypotension or extrapyramidal symptoms.
Major Frameworks/Components:
- ARHGAP10 Gene Variant: A genetic mutation identified in patients that alters the activity of Rho-kinase (ROCK) signaling and neuronal stability.
- ROCK2 (Rho kinase 2): A specific kinase subtype heavily expressed in the brain that regulates brain cell function and neural connectivity.
- KD025: A ROCK2-selective inhibitor utilized to alleviate deficits in working memory, thinking, and visual discrimination.
- Dendritic Spine Density: The structural connectivity of neurons in the prefrontal cortex, which is often degraded in schizophrenia and shown to be restored via selective ROCK2 inhibition.





.jpg)













